Jan Lessem, M.D., Ph.D., FACC

AVP, Clinical and Medical Affairs

Dr. Lessem joined the Abyrx® team in 2016 and currently leads the company’s clinical and medical affairs. Dr. Lessem brings to Abyrx over forty years of large and small company leadership experience designing and executing clinical programs that brought to market several new and important therapeutic products. Prior to Abyrx, Dr. Lessem, was Chief Medical Officer at Advanced BioHealing, a wound healing company that was acquired by Shire (NASDAQ: SHPG) for $750M in 2011, Chief Medical Officer of CombinatoRx, a combination therapy specialty pharmaceutical company that successfully achieved an IPO in 2005, and Chief Medical Officer of Orapharma, an oral health company that achieved an IPO in 2000 and was subsequently acquired by Johnson and Johnson and later by Valeant for a cumulative transaction value over $300M. Previous to Orapharma, Dr. Lessem held various responsibilities for clinical and medical affairs at several public and private companies.

Dr. Lessem received his M.D. and a Ph.D. in Clinical Cardiology from the University of Lund in Sweden. Prior to beginning his career in the specialty pharmaceutical industry, Dr. Lessem became board certified in Cardiology and served as an Associate Professor of Cardiology and Geriatrics at the University of Lund.